›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:SureSeq™ Myeloid MRD Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sysmex CorpType:
Laboratory Developed Test
Related tests:
The SureSeq™ Myeloid MRD Panel has been designed in collaboration with leading cancer experts and in accordance with the European LeukemiaNet (ELN) recommendations to offer a single, cost-effective NGS assay to investigate MRD in AML samples. The panel content incorporates key genes for assessing AML, including genes implicated in MPN and MDS to investigate secondary AML progression.
Cancer:
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Gene:
CALR (Calreticulin), CEBPA (CCAAT Enhancer Binding Protein Alpha), CSF3R (Colony Stimulating Factor 3 Receptor), FLT3 (Fms-related tyrosine kinase 3), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
See More ...
CALR (Calreticulin), CEBPA (CCAAT Enhancer Binding Protein Alpha), CSF3R (Colony Stimulating Factor 3 Receptor), FLT3 (Fms-related tyrosine kinase 3), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), NPM1 (Nucleophosmin 1), RUNX1 (RUNX Family Transcription Factor 1), SF3B1 (Splicing Factor 3b Subunit 1), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
